244 related articles for article (PubMed ID: 18765540)
1. Effective CpG immunotherapy of breast carcinoma prevents but fails to eradicate established brain metastasis.
Xiong Z; Gharagozlou S; Vengco I; Chen W; Ohlfest JR
Clin Cancer Res; 2008 Sep; 14(17):5484-93. PubMed ID: 18765540
[TBL] [Abstract][Full Text] [Related]
2. Potentiation of a dendritic cell vaccine for murine renal cell carcinoma by CpG oligonucleotides.
Chagnon F; Tanguay S; Ozdal OL; Guan M; Ozen ZZ; Ripeau JS; Chevrette M; Elhilali MM; Thompson-Snipes LA
Clin Cancer Res; 2005 Feb; 11(3):1302-11. PubMed ID: 15709202
[TBL] [Abstract][Full Text] [Related]
3. Activation of tumor-specific CD8+ T Cells after intratumoral Ad5-TRAIL/CpG oligodeoxynucleotide combination therapy.
VanOosten RL; Griffith TS
Cancer Res; 2007 Dec; 67(24):11980-90. PubMed ID: 18089829
[TBL] [Abstract][Full Text] [Related]
4. An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen.
Wakita D; Chamoto K; Zhang Y; Narita Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
Int Immunol; 2006 Mar; 18(3):425-34. PubMed ID: 16415100
[TBL] [Abstract][Full Text] [Related]
5. CpG-ODN-based immunotherapy is effective in controlling the growth of metastasized tumor cells.
Kim HA; Ko HM; Ju HW; Kim KJ; Roh SG; Lee HK; Im SY
Cancer Lett; 2009 Feb; 274(1):160-4. PubMed ID: 18952369
[TBL] [Abstract][Full Text] [Related]
6. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients.
Ren T; Wen ZK; Liu ZM; Qian C; Liang YJ; Jin ML; Cai YY; Xu L
Cancer Invest; 2008 Jun; 26(5):448-55. PubMed ID: 18568766
[TBL] [Abstract][Full Text] [Related]
7. Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors.
Daftarian P; Song GY; Ali S; Faynsod M; Longmate J; Diamond DJ; Ellenhorn JD
Cancer Res; 2004 Aug; 64(15):5407-14. PubMed ID: 15289349
[TBL] [Abstract][Full Text] [Related]
8. Eradication of ovarian tumor xenografts by locoregional administration of targeted immunotherapy.
De Cesare M; Calcaterra C; Pratesi G; Gatti L; Zunino F; Mènard S; Balsari A
Clin Cancer Res; 2008 Sep; 14(17):5512-8. PubMed ID: 18765543
[TBL] [Abstract][Full Text] [Related]
9. Immuno-viral therapy of brain tumors by combination of viral therapy with cancer vaccination using a replication-conditional HSV.
Toda M; Iizuka Y; Kawase T; Uyemura K; Kawakami Y
Cancer Gene Ther; 2002 Apr; 9(4):356-64. PubMed ID: 11960286
[TBL] [Abstract][Full Text] [Related]
10. CpG oligodeoxynucleotide-induced immunity prevents growth of germinal center-derived B lymphoma cells.
Ponzio NM; Cutro S; Hu J; Marzouk A; Marshall JD
Int Immunopharmacol; 2006 Dec; 6(13-14):2057-68. PubMed ID: 17161362
[TBL] [Abstract][Full Text] [Related]
11. Combined dendritic cell- and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy.
Heckelsmiller K; Beck S; Rall K; Sipos B; Schlamp A; Tuma E; Rothenfusser S; Endres S; Hartmann G
Eur J Immunol; 2002 Nov; 32(11):3235-45. PubMed ID: 12555669
[TBL] [Abstract][Full Text] [Related]
12. Cancer immunotherapeutic effects of novel CpG ODN in murine tumor model.
Cho HC; Kim BH; Kim K; Park JY; Chang JH; Kim SK
Int Immunopharmacol; 2008 Oct; 8(10):1401-7. PubMed ID: 18687302
[TBL] [Abstract][Full Text] [Related]
13. Cell therapy with preimmunized effector cells mismatched for minor histocompatible antigens in the treatment of a murine mammary carcinoma.
Morecki S; Yacovlev E; Gelfand Y; Uzi I; Slavin S
J Immunother; 2001; 24(2):114-21. PubMed ID: 11265768
[TBL] [Abstract][Full Text] [Related]
14. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity.
Mangsbo SM; Ninalga C; Essand M; Loskog A; Tötterman TH
J Immunother; 2008 Jan; 31(1):34-42. PubMed ID: 18157010
[TBL] [Abstract][Full Text] [Related]
15. [Therapeutic and immunological effects of microwave ablation combined with CpG ODN on transplanted colon carcinoma in mice].
Zou N; Li XF; Ding WM; Lai QH; Zhang JR
Nan Fang Yi Ke Da Xue Xue Bao; 2010 May; 30(5):984-8. PubMed ID: 20501375
[TBL] [Abstract][Full Text] [Related]
16. Genetically targeted T cells eradicate established breast cancer in syngeneic mice.
Wang H; Wei H; Zhang R; Hou S; Li B; Qian W; Zhang D; Kou G; Dai J; Guo Y
Clin Cancer Res; 2009 Feb; 15(3):943-50. PubMed ID: 19188165
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo effects of CpG-Oligodeoxynucleotides (CpG-ODN) on murine transitional cell carcinoma and on the native murine urinary bladder wall.
Olbert PJ; Schrader AJ; Simon C; Dalpke A; Barth P; Hofmann R; Hegele A
Anticancer Res; 2009 Jun; 29(6):2067-76. PubMed ID: 19528466
[TBL] [Abstract][Full Text] [Related]
18. Screening of novel immunostimulatory CpG ODNs and their anti-leukemic effects as immunoadjuvants of tumor vaccines in murine acute lymphoblastic leukemia.
Wang J; Zhang W; He A; Zhao W; Cao X
Oncol Rep; 2011 Feb; 25(2):519-29. PubMed ID: 21165566
[TBL] [Abstract][Full Text] [Related]
19. Implication of macrophages in tumor rejection induced by CpG-oligodeoxynucleotides without antigen.
Auf G; Carpentier AF; Chen L; Le Clanche C; Delattre JY
Clin Cancer Res; 2001 Nov; 7(11):3540-3. PubMed ID: 11705874
[TBL] [Abstract][Full Text] [Related]
20. Adoptive immunotherapy of breast cancer with lymph node cells primed by cryoablation of the primary tumor.
Sabel MS; Arora A; Su G; Chang AE
Cryobiology; 2006 Dec; 53(3):360-6. PubMed ID: 16973145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
